CHINA HEALTH SCIENCES NEWSLETTER
Vol. 4 , No. 18 - November 28, 2003
TOPICS THIS ISSUE:
- Shenzhen Seeks Top Professionals In Europe
- Fast Growing Chinese Biotech Reports 92 Percent Jump in Nine-Month Revenues
- Avid Bioservices Signs Product Development Agreement With Medipharm Biotech For Tumor Necrosis Therapy
- Chongqing Develops Vaccine for Gastric Diseases
Tis the Season for IP Protection |
Shenzhen Seeks Top Professionals In Europe
The Shenzhen government sent a delegation to major European countries in November 2003 to attract 500 professionals, especially Chinese who have studied and worked there, for 55 selected local firms. It's the first time that the government has explored talent resources in the European market; it held three similar employment fairs in the United States in 1992, 2001 and 2002. Apart from some big State-owned enterprises, privately-owned high-tech companies, manufacturing companies, research institutes, hospitals and government departments are participating in the job fair. They provide pay packages worth up to 1 million yuan (US $ 120,481) while some even promise share options. Shenzhen Haowei Group, a privately-owned high-tech company, which attended the previous fairs in the United States, said it has decided to give up to 30 percent shares or options in its wholly-owned subsidiary to candidates. At the US fair last year, the company recruited a manager for its international business who used to work as a chief executive officer of a Silicon Valley company by offering a 1-million-yuan annual pay package and shares. The government-organized employment fairs will be held in London, Paris and Frankfurt, targeting professionals in sectors such as finance, IT, manufacturing, bio-technology and international trade, according to an official announcement. Domestically-listed ZTE Corp will provide the most vacancies, 38, including positions of general engineer for product development and senior project manager. More and more Chinese people are choosing to return to the country to work after finishing their education abroad or working there for some years. About 1,000 have taken up positions in Shenzhen for the first nine months, 40 percent up from a year ago. Of them, 37.2 percent were from European countries, the percentage second only after the United States, according to official figures.
(Source: Financial Times Information)
Are you out-licensing, partnering or in-licensing,
Pharmalicensings global IP exchange can promote your company and technology, for more information go to www.pharmalicensing.com. | |
Fast Growing Chinese Biotech Reports 92 Percent Jump in Nine-Month Revenues
American Oriental Bioengineering Inc., a leading Chinese biotechnology company, recently reported record results for the nine months ended September 30, 2003, reflecting increased demand for the Company's biotechnology, medical and soybean protein peptide products and the company's successful expansion of its market share in China.
Revenue for the nine months ended September 30, 2003 increased 92% to $14.8 million, compared to $7.7 million in the same period a year ago, while revenue for the three months ended September 30, 2003 increased 86% to $5.4 million compared to $2.9 million in the year ago period. The record results reflect a significant increase in demand for the Company's biotechnology, medical and soybean protein peptide products, primarily due to increased consumer usage of the Company's soybean-based nutraceuticals products.
Shujun Liu, Chief Executive Officer of American Oriental Bioengineering, said, "We continue to achieve record growth in our core biotechnology revenues, while improving our profitability and strengthening our balance sheet. We are also pleased with the ongoing progress we are making in operations area. Our existing manufacturing capacity will be dramatically expanded by an additional 2 million tons of soybean per year, once our new 5 million square foot, state-of-the-art technology center is constructed and fully online. Overall, we continue to focus on capturing increased market share of the fast growing Chinese biotechnology market and expanding into overseas markets, while making certain our expenses are aligned with our current business plan."
(Source: World Sources)
Avid Bioservices Signs Product Development Agreement With Medipharm Biotech For Tumor Necrosis Therapy
Avid Bioservices, Inc., a wholly-owned subsidiary of Peregrine Pharmaceuticals announced recently that it has signed a product development agreement with Medipharm Biotech, Co., Ltd. of Shanghai, China for process and product development of Tumor Necrosis Therapy (TNT) under current Good Manufacturing Practices (cGMP). Avid will provide the process development and manufacturing services to assist Medipharm in preparing for commercial launch of their radiolabeled TNT antibody in the Peoples Republic of China (PRC).
"We are very happy to be able to assist Medipharm as they make preparations for the commercial launch of TNT," said Jay Treat, Ph.D., Avid's vice president of business development. "This is a comprehensive project in which Avid will provide process development, scale-up and cGMP manufacturing of Medipharm's TNT monoclonal antibody."
MediPharm received product approval for Iodine-131 radiolabeled Tumor Necrosis Therapy (TNT) monoclonal antibody in the Peoples Republic of China. The issuance of the Certificate of New Drug from the State Food and Drug Administration (SFDA) of China for Iodine-131 radiolabeled Tumor Necrosis Therapy (TNT) monoclonal antibody for the treatment of advanced lung cancer represents the first radiolabeled monoclonal antibody approved for cancer therapy in China.
(Source: PR Newswire)
Chongqing Develops Vaccine for Gastric Diseases
On November 18, 2003, The Third Military Medical University (TTMMU) unveiled one kind of vaccine for gastric diseases in its genetic engineering projects, which was researched and developed by TTMMU. At the same time, it is also the world's first kind of vaccine for gastric diseases. Its name is Helicobacter Pylori Vaccine (HPV). In addition, World Health Organization (WHO) has determined that HPV is one of its key projects in the coming 10 years.
Through more than 10 years of efforts, TTMMU eventually developed the first oral HPV around the globe. The move has always been sponsored by the National 863 Plans, and key technological projects of China's 9th Five-year-plan.
Animal experiments reveal that HPV's immune effect reaches over90%, and oral HPV will function for 10 to 15 years. In May 2003, State Food and Drug Administration of the People's Republic of China (SFDA) approved that TTMMU began clinic experiments. If successful, TTMMU will commence production of HPV in 2005.
(Source: Comtex News Network)
Lehman Lee & Xu
A Licensed Chinese Law Partnership
http://www.lehmanlaw.com
Beijing Office | Shanghai Office |
6th floor, Dongwai Diplomatic Office Building
23 Dongzhimenwai Dajie
Beijing 100600 China
Tel.: (86)(10) 8532-1919
Fax: (86)(10) 8532-1999
Email: mail@lehmanlaw.com | Suite 1310, Kerry Centre
No. 1515, West Nanjing Road
Shanghai 200040 China
Tel: (86)(21) 5298-5252
Fax:(86)(21) 6288-2699
Email: shanghai@lehmanlaw.com |
The China Health Sciences Newsletter is intended to be used for news purposes only. It should not be taken as comprehensive legal advice, and Lehman, Lee & Xu will not be held responsible for any such reliance on its contents.
Unsubscribe |
Internet Explorer users, please click here: hs@lehmanlaw.com?subject=Remove%20Health%20Sciences%20%21*ADDITIONAL_FIELD1*%21 |
Netscape users, please send email to: hs@lehmanlaw.com
with
Remove Health Sciences !*ADDITIONAL_FIELD1*!
in the Subject Line. |
